戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nded normally to cold stimulation and in the formalin test.
2 tory hyperalgesia was investigated using the formalin test.
3 e to morphine in both the tail-flick and the formalin test.
4 ifensive responses to persistent pain in the formalin test.
5 ole of electrolytic lesions to the MT in the formalin test.
6 t affect inflammatory pain measured with the formalin test.
7 ve effect of intrathecal morphine in the rat formalin test.
8 to those seen in the second phase of the paw formalin test.
9  in spinal nociceptive processing during the formalin test.
10  (DAMGO) and delta- (deltorphin) ORAs in the formalin test.
11 vely knocked-down the KOR as assessed in the formalin test.
12 ery nociceptive behavior was assessed by the formalin test.
13 t bicuculline enhances pain behaviors in the formalin test.
14 ngly, only one of these was effective in the formalin test.
15 se to a chemical nociceptive stimulus in the formalin test.
16 rally into this area was evaluated using the formalin test.
17 ated the nociceptive responses solely in the formalin test.
18 tion of systemic morphine bilaterally in the formalin test.
19  a reduction in nocifensive behaviors in the formalin test.
20 ve behavior in the inflammatory phase of the formalin test.
21 d pain sensitivity in both the hot plate and formalin tests.
22 g catalepsy, and hypoalgesia in hotplate and formalin tests.
23    Derm-sap treatment had two effects in the formalin test: (1) increased baseline nocifensive respon
24 s during the prolonged, tonic portion of the formalin test (20-35 min).
25 ently attenuated nociceptive behavior in the formalin test, a rat model of tonic pain.
26 e to measure glial activation in vivo in the formalin test, a standard orofacial inflammatory pain mo
27 of 11, 22, and 26 was evaluated in the mouse formalin test (A3AR antagonist blocked and A3AR agonist
28  hypersensitivity to the second phase of the formalin test and chronic constriction injury.
29 istent inflammatory stimuli in male mice, in formalin test and dextran sodium sulfate (DSS)-induced c
30 l CSF coincides with phase 2 behavior in the formalin test and may contribute to spinal nociceptive p
31 ed c-fos expression in rats having undergone formalin testing and by electrophysiological recording o
32 assays of acute pain: the acute phase of the formalin test, and the thermal (49 degrees C) tail-flick
33                                    Using the formalin test as a mouse model of persistent inflammator
34 king behavior during the second phase of the formalin tests as compared to sham lesion controls.
35 gnificant decrease in the first phase of the formalin test, but in male mice only.
36 led to reduce phase 2 flinching in the mouse formalin test even at a dose of 100 mpk PO due to insuff
37                                              Formalin testing evoked c-fos expression in these pontos
38 tically significant analgesic effects in the formalin test for acute inflammatory pain and paclitaxel
39  licking behavior in the second phase of the formalin test in animals with ACC lesions.
40         CART produces antinociception in the formalin test in both phases.
41 pendent differences in nociception using the formalin test in mice.
42 ,212-2 suppressed tonic pain behavior in the formalin test in sham-operated rats during phase 2 (15-6
43  nociceptive responses in the tail flick and formalin tests in mice.
44 ensive behaviours in the second phase of the formalin test (not observed in LGI1fl/Nav1.8+ mice), and
45 nverse agonists was confirmed in vivo in the formalin test of acute peripheral and inflammatory pain
46 rly and late phases of the mouse intradermal formalin test of pain, and this in vivo effect was rever
47 at B imaging probe only slightly altered the formalin test results.
48 me assay; in the tonic phase of the biphasic formalin test, the ED50 was 129+/-32 mg/kg.
49 K-801 each blocked morphine tolerance in the formalin test, the effect of ACEA-1328 was dose-dependen
50 extracellular Cat B in activated glia in the formalin test using a NIR imaging probe.
51  their response during the late phase of the formalin test was attenuated.
52 tinociceptive activity in both phases of the formalin test, whereas E121 had activity only in phase 1
53 pain) and phase 2 (inflammatory pain) of the formalin test, whereas indomethacin had activity only in
54 ed DPDPE analgesia is also demonstrated upon formalin testing, while the nonpeptide delta agonist BW3